JP2020526553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526553A5 JP2020526553A5 JP2020501279A JP2020501279A JP2020526553A5 JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5 JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- aln
- composition according
- body weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims 10
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 101000629622 Homo sapiens Serine-pyruvate aminotransferase Proteins 0.000 claims 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 claims 6
- 230000029142 excretion Effects 0.000 claims 6
- 208000000891 primary hyperoxaluria type 1 Diseases 0.000 claims 6
- 230000002485 urinary effect Effects 0.000 claims 6
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 claims 4
- 101001031589 Homo sapiens 2-Hydroxyacid oxidase 1 Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023134504A JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532176P | 2017-07-13 | 2017-07-13 | |
| US62/532,176 | 2017-07-13 | ||
| US201762581565P | 2017-11-03 | 2017-11-03 | |
| US62/581,565 | 2017-11-03 | ||
| US201862646285P | 2018-03-21 | 2018-03-21 | |
| US62/646,285 | 2018-03-21 | ||
| US201862682020P | 2018-06-07 | 2018-06-07 | |
| US62/682,020 | 2018-06-07 | ||
| PCT/US2018/041891 WO2019014491A1 (en) | 2017-07-13 | 2018-07-12 | METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Division JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526553A JP2020526553A (ja) | 2020-08-31 |
| JP2020526553A5 true JP2020526553A5 (enExample) | 2021-08-12 |
| JP7337044B2 JP7337044B2 (ja) | 2023-09-01 |
Family
ID=65002248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501279A Active JP7337044B2 (ja) | 2017-07-13 | 2018-07-12 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11261447B2 (enExample) |
| EP (1) | EP3651775A4 (enExample) |
| JP (2) | JP7337044B2 (enExample) |
| AU (2) | AU2018301829B2 (enExample) |
| CA (1) | CA3069451A1 (enExample) |
| WO (1) | WO2019014491A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| US11261447B2 (en) | 2017-07-13 | 2022-03-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| IL320582A (en) | 2019-11-01 | 2025-07-01 | Lilac Therapeutics Inc | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| WO2021188611A1 (en) * | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| EP4232581A1 (en) * | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| CA3201452A1 (en) * | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| EP4043018A1 (en) | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
| EP4373934A1 (en) * | 2021-07-19 | 2024-05-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| US7786290B2 (en) | 2003-06-13 | 2010-08-31 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| WO2005089287A2 (en) | 2004-03-15 | 2005-09-29 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| CA2603730A1 (en) | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| KR101362681B1 (ko) | 2006-03-31 | 2014-02-13 | 알닐람 파마슈티칼스 인코포레이티드 | Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법 |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| US20110045593A1 (en) | 2009-08-19 | 2011-02-24 | TransAlgae (Israel) Ltd. | Transgenically mitigating the establishment and spread of transgenic algae in natural ecosystems by suppressing the activity of carbonic anhydrase |
| RS54578B1 (sr) | 2010-02-24 | 2016-06-30 | Arrowhead Research Corporation | Preparati za ciljano dopremanje sirnk |
| US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
| FI3366775T4 (fi) | 2011-11-18 | 2025-11-14 | Alnylam Pharmaceuticals Inc | Modifioituja rnai-agensseja |
| AU2012340159B2 (en) | 2011-11-18 | 2017-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP4253395A3 (en) | 2012-08-06 | 2023-11-29 | Alnylam Pharmaceuticals, Inc. | Processes for the preparation of carbohydrate conjugated rna agents |
| KR102605775B1 (ko) | 2013-03-14 | 2023-11-29 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법 |
| ES2875558T3 (es) | 2013-12-27 | 2021-11-10 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de glicolato oxidasa (HAO1) por ARN de doble cadena |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| TW201718857A (zh) * | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | 用於抑制alas1基因表現之組合物及方法 |
| US11261447B2 (en) | 2017-07-13 | 2022-03-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
-
2018
- 2018-07-12 US US16/630,800 patent/US11261447B2/en active Active
- 2018-07-12 WO PCT/US2018/041891 patent/WO2019014491A1/en not_active Ceased
- 2018-07-12 JP JP2020501279A patent/JP7337044B2/ja active Active
- 2018-07-12 AU AU2018301829A patent/AU2018301829B2/en active Active
- 2018-07-12 EP EP18831099.9A patent/EP3651775A4/en active Pending
- 2018-07-12 CA CA3069451A patent/CA3069451A1/en active Pending
-
2022
- 2022-01-20 US US17/579,655 patent/US20220403394A1/en active Pending
-
2023
- 2023-08-22 JP JP2023134504A patent/JP7767365B2/ja active Active
-
2024
- 2024-10-21 AU AU2024227498A patent/AU2024227498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526553A5 (enExample) | ||
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| JP2014530226A5 (enExample) | ||
| JP2017502017A5 (enExample) | ||
| JP2011519364A5 (enExample) | ||
| NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
| RU2015100529A (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан | |
| JP2017503820A5 (enExample) | ||
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2018514510A5 (enExample) | ||
| EP4342985A3 (en) | Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components | |
| TNSN06308A1 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| EA201101036A1 (ru) | Применение хлорида аммония в терапии | |
| JP2021004249A5 (enExample) | ||
| FI3930686T3 (fi) | Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2019535830A5 (enExample) | ||
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| JP2011500650A5 (enExample) | ||
| JP2005529152A5 (enExample) | ||
| RU2018129076A (ru) | Составы оритаванцина | |
| PH12021552573A1 (en) | Long-term stable live fecal microbiota composition | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| Fukao et al. | Delayed dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and mortality in mice infected with influenza a virus |